Markets | | | Despite their shares taking a heavy beating with the rest of the equity market in March, over the past few weeks Peloton (NASDAQ: PTON) has joined the ranks of stocks that ended up hitting fresh all time highs in the face of the coronavirus pandemic. In light of many non-essential businesses shuttin... Read the Full Story |
|
From Our PartnersAfter May 27, your mornings might NEVER be the same.
You see, we’ve secured your spot for the 930 Profit Summit Wednesday, May 27 at 1pm EST.
For the first time ever, America’s #1 morning trader Tim Sykes is hosting a summit to reveal this new way of making money as soon as the market opens at 930 AM. | | Just click here to claim your spot… FREE of charge. |
|
Markets | | | Clorox Is The #1 Bet For Pandemic-Driven Gains
Clorox (CLX) reported earnings for the first quarter last week and gave what I called then a “goldilocks report”. The headline figures were above consensus, they showed growth from the previous year, and were backed up by internal data that... Read the Full Story |
|
Markets | | |
Latin America is a region of the world that seems to be a little late to the party in terms of adapting e-commerce into their everyday life. However, that seems to be changing fast thanks to MercadoLibre (NASDAQ:MELI), which is a rapidly growing online commerce and payments business. The company r... Read the Full Story |
|
From Our PartnersThe recent market sell-off has sent some investors heading for safety. The S&P 500 and other major indexes lost over 30% of their value.
And even with the recent stock market rally, many of the major indexes are down by over 20% for the year. Who would have predicted that in January?
In that context, the biotech sector looks less bad than the market. The iShares NASDAQ Biotechnology Index ETF is “only” down a little over 10% for the year. And the reason for the strength in biotechs is the same as the reason for the sell-off in the broader market, the coronavirus.
Or in this case, the possibility of a vaccine or antiviral treatment. As part of the $6 trillion dollars that the federal government is throwing at the coronavirus crisis, biotechs that are developing vaccines or other treatments stand to get a direct infusion of cash.
But vaccines are tricky things. Being first matters. And so many companies that are developing vaccines will not be the ones that bring them to market. And that means that any gains in their stock are a shot in the dark.
There is, however, a strategy you can use to ensure you are getting a return that is more than just less bad. And to execute this strategy you have to pay close attention to a company’s pipeline. What drugs do they have on the market, and what do they have in development?
Some of these companies are on the forefront of the fight against the coronavirus. Many however are not. But they are developing cutting edge drugs for cancer, diabetes, and cystic fibrosis. These are diseases that have been around longer than the coronavirus and will still be plaguing our population long after we’ve made the coronavirus (hopefully) a distant memory.
We’ve put together this presentation that highlights eight such companies. We invite you to spend some time becoming familiar with these companies so you can see your portfolio thrive, and not survive, in these turbulent times. | | Click Here to View the Stocks |
|
Markets | | |
As volatile as the stock market has been for the last couple of months now, the cryptocurrency market has been that volatile for years now. Bitcoin, pretty much the gold standard in cryptocurrency, has seen wild changes in valuation just in the last year. The price over the last year retested the ... Read the Full Story |
|
Markets | | |
On Friday, May 8 Kimco Realty (NYSE:KIM) posted a positive first-quarter earnings report. For a real estate investment trust (REIT), the quarterly funds from operation (FFO) is a critical metric. And Kimco delivered FFO of 37 cents per share. This beat analysts’ estimates for 36 cents per sh... Read the Full Story |
|
|
The Early Bird Stock Of The Day Avangrid, Inc., an energy services holding company, engages in the regulated energy transmission and distribution, and renewable energy generation businesses in the United States. The company operates through Networks and Renewables segments. It is involved in the generation, transmission, and distribution of electricity; and distribution, transportation, and sale of natural gas. In addition, the company operates renewable energy generation facilities primarily using onshore wind power, as well as solar, biomass, and thermal power. Further, it delivers natural gas and electricity to residential, commercial, and institutional customers through its regulated utilities in New York, Maine, Connecticut, and Massachusetts; and sells its output to investor-owned utilities, public utilities, and other credit-worthy entities, as well as generates and provides power and other services to federal and state agencies, institutional retail, and joint action agencies. Additionally, the company delivers thermal output to wholesale customers in the Western United States. It owns eight electric and natural gas utilities, serving 3.3 million customers in New York and New England, as well as owns and operates 9.3 gigawatts of electricity capacity primarily through wind power in 22 states. Avangrid, Inc. was incorporated in 1997 and is headquartered in Orange, Connecticut. The company operates as a subsidiary of Iberdrola, S.A. | | View Today's Stock Pick |
|
